Hims & Hers Surges 34% After Lawsuit Settlement, Sets $23 and $28 Targets
Hims & Hers surged 34.47% last week to $22.16 after striking a distribution partnership to end Novo Nordisk’s lawsuit, removing a major legal overhang. BofA upgraded the stock to Neutral with a $23 target while Deutsche Bank retained Hold but raised its price objective to $28.
1. Lawsuit Resolution and Partnership
Hims & Hers ended its legal dispute with Novo Nordisk by agreeing to a distribution partnership for GLP-1 medicines, eliminating a significant legal overhang and reducing regulatory scrutiny tied to compounded semaglutide.
2. Analyst Upgrades and Price Targets
BofA upgraded Hims & Hers from Underperform to Neutral and set a $23 price target, while Deutsche Bank maintained a Hold rating but lifted its price objective to $28, highlighting a more balanced risk/reward profile after the legal cloud cleared.
3. Stock Performance and Financial Snapshot
The shares climbed 34.47% over the past week to $22.16 and remain down 31.75% year to date. FY2025 revenue reached $2.35 billion, up 59% year over year, and 2026 guidance calls for $2.70 billion to $2.90 billion supported by over 2.5 million subscribers.